14,210 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by Fairfield Financial Advisors LTD

Fairfield Financial Advisors LTD bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 14,210 shares of the company’s stock, valued at approximately $12,866,000. Eli Lilly and Company accounts for about 4.5% of Fairfield Financial Advisors LTD’s investment portfolio, making the stock its 7th largest holding.

Several other institutional investors and hedge funds also recently bought and sold shares of LLY. Brown Brothers Harriman & Co. increased its stake in Eli Lilly and Company by 16.2% during the second quarter. Brown Brothers Harriman & Co. now owns 18,660 shares of the company’s stock worth $16,894,000 after acquiring an additional 2,599 shares during the last quarter. Quilter Plc grew its holdings in shares of Eli Lilly and Company by 9.9% during the 2nd quarter. Quilter Plc now owns 8,888 shares of the company’s stock worth $8,047,000 after purchasing an additional 800 shares during the period. Tennessee Valley Asset Management Partners increased its position in shares of Eli Lilly and Company by 25.2% during the 2nd quarter. Tennessee Valley Asset Management Partners now owns 373 shares of the company’s stock worth $338,000 after purchasing an additional 75 shares during the last quarter. Rathbones Group PLC raised its holdings in Eli Lilly and Company by 33.1% in the 2nd quarter. Rathbones Group PLC now owns 129,360 shares of the company’s stock valued at $117,120,000 after buying an additional 32,152 shares during the period. Finally, Plato Investment Management Ltd lifted its position in Eli Lilly and Company by 5.4% in the second quarter. Plato Investment Management Ltd now owns 15,323 shares of the company’s stock valued at $13,873,000 after buying an additional 783 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Morgan Stanley restated an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Citigroup assumed coverage on Eli Lilly and Company in a report on Friday. They issued a “buy” rating and a $1,060.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Stock Down 1.2 %

Shares of NYSE:LLY opened at $923.71 on Monday. The firm has a 50 day simple moving average of $897.12 and a 200-day simple moving average of $833.89. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company has a market capitalization of $877.92 billion, a PE ratio of 136.04, a P/E/G ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, equities analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 451,900 shares of company stock valued at $418,732,178 over the last quarter. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.